Background: Anti-thyroid drugs (ATD) are routinely used in Australian practice as first-line therapy for Graves’ hyperthyroidism (GH) prior to 131I (radioiodine) treatment. There is concern that patients who do not receive ATD pre-treatment will develop uncontrolled hyperthyroidism before and after 131I therapy and that 131I therapy without ATD pre-treatment may not be as efficacious as with AT...

Development of biocompatible/biodegradable materials with multiple functionalities via simple methods for cancer combination therapy has attracted great attention in recent years. Herein, paclitaxel (PTX), a popular anti-tumor chemotherapeutic drug, is used to induce the self-assembly of human serum albumin (HSA) pre-labeled with radionuclide I-131, obtaining 131I-HSA-PTX nanoparticles for comb...

UNLABELLED To evaluate the possibility of radionuclide gene therapy and imaging in hepatocellular carcinoma cancer, we investigated the iodine accumulation of a human hepatocellular carcinoma cell line, SK-Hep1, by transfer of human sodium iodide symporter (hNIS) gene. By targeting NIS expression in SK-Hep1, we could also investigate whether these cells concentrate 99mTc-pertechnetate and 188Re...

This study aimed to compare the efficacy of 131I therapy between elderly and non-elderly patients with lung metastasis of differentiated thyroid cancer (DTC). Thirty-eight patients diagnosed with lung metastasis of DTC were divided into elderly group (60-80 years old; 17 cases) and non-elderly (33-59 years old; 21 cases). All patients received 131I therapy following the total thyroidectomy. Aft...

Diagnostic whole-body scan is a standard procedure in patients with thyroid cancer prior to the application of a therapeutic dose of 131I. Unfortunately, administration of the radioisotope in a diagnostic dose may decrease further radioiodine uptake-the phenomenon called "thyroid stunning". We estimated radiation absorbed dose-dependent changes in genetic material, in particular in the sodium i...

Introduction Radiolabeled gold nanoparticles play an important role in biomedical application. The aim of this study was to prepare iodine-131 (131I)-labeled gold nanorods (GNRs) conjugated with cyclic RGD and evaluate its biological characteristics for targeted imaging of integrin αvβ3-expressing tumors. Methods HS-PEG(5000)-COOH molecules were applied to replace CTAB covering the surface of...

The anti-carcinoembryonic antigen murine monoclonal antibody MAb35 and its F(ab')2 fragment were labeled with 131I or the potential therapeutic nuclide 67Cu. In vivo distribution patterns were compared in nude mice bearing human tumor xenografts by coinjection of the 131I- and 67Cu-labeled materials, thereby minimizing variations due to xenograft and host animal. The results showed that the 67C...

We compared the diagnostic sensitivities of 123I and 131I whole-body imaging in differentiated thyroid cancer. Methods: Twelve thyroidectomized patients (3 previously treated with 131I) were studied. After a period of thyroid hormone withdrawal, whole-body imaging was performed approximately 24 and 72–96 h after administration of 74 –185 MBq (2–5 mCi) 123I and 111–185 MBq (3–5 mCi) 131I, respec...

Pharmacokinetic and biodistribution studies were conducted in rats on a novel serine protease inhibitor, LEX 032, that was radiolabeled with 131I by the Bolton-Hunter reagent. LEX 032, a genetically engineered recombinant human nonglycosylated serpin, has been shown to have antiinflammatory properties in a number of animal models of inflammation and reperfusion injury. When 131I-LEX 032 was inj...